Mr. Bloom is a co-founder of Bloom Burton & Co. and serves as the firm’s President and Head of Institutional Sales and capital market activities. By forging unique relationships with international healthcare-specialized investors, he attracts capital for growing companies seeking to accelerate returns for investors. Before co-founding Bloom Burton, Mr. Bloom spent six years at Dundee Securities in the Healthcare and Biotechnology Institutional Sales and Equity Research groups. Earlier in his career, he spent two years in the equity research group at a New York-based merchant banking firm, SCO Group, and was an investment banking analyst at M&A advisory firm, Molecular Securities. Mr. Bloom is a member of the Life Sciences Advisory Board at the National Research Council of Canada and the Board of Directors at BIOTECanada. Brian also serves on the Board of Directors of the Baycrest Foundation and the Advisory Board of the Cell Therapy Program at Princess Margaret Hospital.
John Holyoake, DPhil
John Holyoake, Vice President, Investment Banking, joined Bloom Burton & Co. in January 2012. At Bloom Burton, John’s responsibilities include M&A advisory and monetization planning, as well as conducting technical and commercial due diligence of companies across all healthcare sectors. John’s area of expertise spans early-stage technologies to profitable healthcare service companies, with a particular focus on preclinical-stage biotech. John has previous industry experience with the clinical stage oncology company TenX BioPharma and the life science consulting group SHI Link, as well as with several early-stage life science companies. He currently serves on the Board of directors of Triumvira Immunologics and Appili Therapeutics. John holds a Master’s in Biochemistry and Doctorate from the University of Oxford, and made the transition across the Atlantic for a post-doctoral research fellowship at The Hospital for Sick Children, Toronto.
Kevin Sullivan, MBA
Mr. Sullivan has over 15 years of experience working with early stage biotechnology companies and has raised over $37M in private equity and non-dilutive government funding in biotechnology. Most recently he was Chief Executive Officer at DeNovaMed Inc., a biotechnology company focused on development of Gram-negative and Gram-positive antibiotics. Previously, he was Chief Operating Officer at Viron Therapeutics, a biopharmaceutical company developing a novel immunotherapy and recipient of the Prix Galien Award for Biotechnology. At Viron, he and his team completed development of the Company’s lead program through Phase 2 clinical development with Series A and B financing from a syndicate of international venture capital including two pharma-venture participants. He is an active mentor and volunteer advisor for several start-up biotechnology companies. Mr. Sullivan received a BSc in Immunology from Dalhousie University, a Graduate Certificate in Biotechnology from McGill University and an MBA from Western University.
Dr. Lidija Marusic
Dr. Lidija Marusic is an investment manager at Innovacorp, a venture capital fund investing in seed and early-stage technology companies. With over 15 years of experience in life science technology commercialization, Lidija manages all aspects of the investment due diligence, approval and closing cycle, and works hands-on with Innovacorp’s portfolio companies. Prior to joining Innovacorp, Lidija worked at MDS Capital Corp. (now Lumira Capital) and its seed fund MedInnova Partners Inc., focusing on commercializing biomedical discoveries. Lidija holds a Doctor of Medicine degree from the University of Zagreb, a PhD in molecular genetics from the International School for Advanced Studies (SISSA/ISAS) and an MBA from McMaster University. She served on the International Peer Review Panel for the Canadian Networks of Centres of Excellence (NCE) and on the Proof of Principle Peer Review Committee of the Canadian Institutes for Health Research (CIHR). Lidija is a member of the board of directors for DeCell Technologies Inc., DGI Clinical Inc. and DeNovaMed Inc., and a board observer at ABK Biomedical Inc. and Densitas Inc.
Mr. Nicolle has 20 years of experience leading companies and growing shareholder value. He is currently president of Cape Bear Advisors where he consults and holds numerous board positions, including vice chair of the start-up accelerator Propel ICT. Mr. Nicolle is the former CEO of leading healthcare technology company, STI Technologies, where he negotiated agreements with top pharmaceutical companies resulting in an increase in revenue of 500 per cent. Before STI Technologies Mr. Nicolle spent 10 years leading venture-backed technology companies, including: CEO of Tatara Systems, CEO of Sigma Systems, COO at March Networks, and President of Nortel’s Service Provider eBusiness Solutions Group. He is a graduate of Western University with an honours degree in computer science.